Dioletis Evangelos, Paiva Ricardo S, Kaffe Eleanna, Secor Eric R, Weiss Theresa R, Fields Maxine R, Ouyang Xinshou, Ali Ather
Internal Medicine (Digestive Diseases), Yale University School of Medicine, One Gilbert Street, TAC Bldg, Room #S241, New Haven, CT, 06519, USA.
Hartford Hospital and University of Connecticut, Hartford, CT, USA.
BMC Nutr. 2021 Mar 4;7(1):6. doi: 10.1186/s40795-021-00408-4.
Soy products are associated with many beneficial health consequences, but their effects on the human intestinal microbiome are poorly characterized.
To identify the changes in the oral and fecal microbiome in lean and obese participants due to consumption of Q-CAN®, and to assess the expected consequences of these changes based on the published literature.
Prospective study of lean (10) and obese (9) participants consuming Q-CAN® twice daily for 4 weeks with 8 weeks follow-up. Microbial DNA was extracted from saliva and stool samples, amplified against the V4 region of the 16S ribosomal RNA gene and data analyzed using QIIME 1.9.1 bioinformatics. Four hundred forty-four samples were collected in total, 424 of which were productive and yielded good quality data.
STOOL. In the lean population Bifidobacteria and Blautia show a significant increase while taking Q-CAN®, and there was a trend for this in the obese population. ORAL. There were relatively fewer major changes in the oral microbiome with an increase in the family Veillonellaceae in the lean population while on Q-CAN®.
Q-CAN® consumption induced a number of significant changes in the fecal and oral microbiome. Most notably an increase in the stool microbiome of Bifidobacteria and Blautia, both of which are associated with positive health benefits, and in the saliva an increase in Veillonellaceae.
This trial was registered with Clinicaltrials.gov on January 14th 2016. ClinicalTrials.gov Identifier: NCT02656056.
豆制品与许多有益健康的结果相关，但它们对人类肠道微生物群的影响却鲜为人知。
确定瘦人和肥胖参与者食用Q-CAN®后口腔和粪便微生物群的变化，并根据已发表的文献评估这些变化的预期后果。
对10名瘦人和9名肥胖参与者进行前瞻性研究，他们每天服用两次Q-CAN®，持续4周，并进行8周的随访。从唾液和粪便样本中提取微生物DNA，针对16S核糖体RNA基因的V4区域进行扩增，并使用QIIME 1.9.1生物信息学软件分析数据。总共收集了444个样本，其中424个样本有效并产生了高质量的数据。
粪便：在瘦人群体中，服用Q-CAN®期间双歧杆菌和布劳特氏菌显著增加，肥胖人群中也有这种趋势。口腔：口腔微生物群的主要变化相对较少，瘦人群体在服用Q-CAN®期间韦荣氏菌科有所增加。
食用Q-CAN®导致粪便和口腔微生物群发生了许多显著变化。最明显的是，粪便微生物群中的双歧杆菌和布劳特氏菌增加，这两者都与积极的健康益处相关，并且唾液中的韦荣氏菌科增加。
该试验于2016年1月14日在Clinicaltrials.gov上注册。ClinicalTrials.gov标识符：NCT02656056。
